

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Singapore Exchange Securities Trading Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED

康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Hong Kong Stock Code: 867)

(Singapore Stock Code: 8A8)

Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Overweight/Obesity Indication of Self-Developed Innovative Drug INHBE-Targeting Small Nucleic Acid Drug CMS-D008

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.

Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal function of body fat. World Obesity Atlas 2025 Report projected

that the global proportion of overweight and obesity adults will rise to 50%, affecting nearly 3 billion adults impacted by high body mass index (BMI) and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric empty. INHBE's novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE is associated with favorable fat distribution and beneficial metabolic characteristics. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.

CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group's R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group's mature network resources in the field of cardiovascular and metabolic diseases, the drug's R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.

The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.

This announcement is made on a voluntary basis and aims to inform potential investors and shareholders of the Company of the latest business developments of the Group. Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 4 March 2026

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong and Ms. Chen Yanling as executive directors; (ii) Mr. Leung Chong Shun, Ms. Luo Laura Ying and Mr. Fung Ching Simon as independent non-executive directors.